8 min watch
Impact of intolerance on patient goals
Patient portrayal.
Quinn is a mother of 3 and is constantly in motion. While achieving a durable response from her CML treatment, she deals with an ongoing AE that disrupts her active lifestyle.
Quinn has noted that her persistent AE has become intolerable, and is experiencing fatigue that is slowing her down and not allowing her to keep up with her kids’ extracurricular activities. How would that influence your clinical assessment?
-
Sokal Risk Score
- Low risk (0.7)
-
Time Since Diagnosis
- 36 months
-
Current Treatment
- 2nd-line TKI
-
Length of Time on Current Treatment
- 12 Months
-
Molecular Status
- 0.5% BCR-ABL1
-
Persistent AEs
- Grade 2 fatigue
According to the National Comprehensive Cancer Network® (NCCN®), patients with >0.1% to 1% BCR-ABL1 at 12 months have TKI-sensitive disease and patient goals may influence clinical considerations1
Monitoring a patient close to CCyR
Patient portrayal.
George is retired and a proud grandfather of 4 who wants to be active with his family. Has he achieved optimal control of his disease?
George’s response may be plateauing. He started skipping doses because his AEs were disrupting his daily life and keeping him up late at night. Could skipping doses because of his AEs impact his response? Could he be resistant?
-
Sokal Risk Score
- Low risk (0.7)
-
Time Since Diagnosis
- 48 months
-
Current Treatment
- 2nd-line TKI
-
Length of Time on Current Treatment
- 12 Months
-
Molecular Status
- 1.1% BCR-ABL1
-
Persistent AEs
- Grade 1 diarrhea
- Grade 2 nausea
According to the NCCN, patients with >1% to 10% BCR-ABL1 at 12 months have possible TKI resistance1
How do you assess early signs of resistance?
Patient portrayal.
Susan enjoys volunteering and spending time with her family. She wants to get back to focusing on the joys of her daily life.
Susan is showing early signs of potential resistance to her current treatment. How would you evaluate the appropriate CML treatment approach for a patient like Susan?
-
Sokal Risk Score
- Intermediate risk (1.2)
-
Time Since Diagnosis
- 15 months
-
Current Treatment
- 2nd-line TKI
-
Length of Time on Current Treatment
- 3 months
-
Molecular Status
- 12% BCR-ABL1
-
Persistent AEs
- Grade 2 rash
According to the NCCN, patients with >10% BCR-ABL1 at 3 months have possible TKI resistance1
Back to top